DiaMedica Therapeutics (DMAC) Cash from Operations (2018 - 2026)

DiaMedica Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 9082000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 27.04% year-over-year to 9082000.0 in Q1 2026; TTM through Mar 2026 was 30995000.0, a 37.32% decrease from a year earlier, with the FY2025 full-year figure at 29062000.0, down 31.65% from the prior year.
• Cash from Operations declined to 9082000.0 in Q1 2026 per DMAC's latest filing, from 7762000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 2361000.0 in Q3 2022 and bottomed at 9082000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 5030000.0 (2023), against an average of 5321117.65.
• Across the five-year window, Cash from Operations increased 22.49% in 2022 and sank 103.18% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 2766000.0 in 2022, then sank by 37.82% to 3812000.0 in 2023, then sank by 68.78% to 6434000.0 in 2024, then retreated by 20.64% to 7762000.0 in 2025, then fell by 17.01% to 9082000.0 in 2026.
• Per Business Quant, the three latest DMAC Cash from Operations figures stand at 9082000.0 (Q1 2026), 7762000.0 (Q4 2025), and 6553000.0 (Q3 2025).